Perspective Therapeutics (CATX) Announces 1-for-10 Reverse Stock Split

Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective's common stock is expected to begin trading on the NYSE American on a split-adjusted basis under the existing trading symbol "CATX" and new CUSIP number 46489V302.

At Perspective's annual meeting of stockholders on May 31, 2024, Perspective's stockholders approved a proposal to authorize Perspective's Board of Directors to file an amendment to the Company's certificate of incorporation to effect the reverse stock split at a ratio of 1-for-10. The reverse stock split will be effected by filing a Certificate of Amendment to Perspective's certificate of incorporation with the Secretary of State of the State of Delaware.

As a result of the reverse stock split, each 10 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, resulting in the number of outstanding shares of Perspective's common stock being reduced from approximately 674.3 million to approximately 67.4 million immediately following the effectiveness of the reverse stock split.

The reverse split will affect all issued and outstanding shares of Perspective's common stock. The reverse split will not reduce the total number of authorized shares of the Company's common stock or preferred stock, or change the par values of the Company's common stock or preferred stock. The reverse split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the Company's shares of common stock (except to the extent that the reverse split would result in some of the stockholders receiving cash in lieu of fractional shares). Stockholders will receive cash in lieu of fractional shares based on the closing price per share of the common stock as reported on the NYSE American on June 14, 2024 (as adjusted to give effect to the reverse split).

All outstanding options and warrants entitling their holders to purchase shares of the Company's common stock will be adjusted as a result of the reverse split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Company's equity incentive plans will also be appropriately adjusted.

Computershare Trust Company, N.A. ("Computershare") is acting as the exchange agent and transfer agent for the reverse stock split. Computershare will provide instructions to stockholders with physical certificates regarding the process for exchanging their pre-split stock certificates for post-split shares in book-entry form and receiving payment for any fractional shares.

Additional information regarding the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 18, 2024, which is available free of charge on the SEC's website at www.sec.gov and on the Company's website at www.perspectivetherapeutics.com.

You May Also Be Interested In

• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• Zentek shares to move from Nasdaq to OTC Markets on Sept. 2
• FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera